ARTH / Arch Therapeutics, Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2024 ARCH THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

EX-16.1

Exhibit 16.1

Arch Therapeutics, Inc. 235 Walnut St., Suite 6 Framingham, MA 01760

Arch Therapeutics, Inc. 235 Walnut St., Suite 6 Framingham, MA 01760 May 23, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Office of Industrial Applications and Services Washington, D.C. 20549 Re: Arch Therapeutics, Inc. Request for Withdrawal of Registration Statement on Form S-1 File No. 333-268008 Ladies and Gentlemen: Pursuant to Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 ARCH THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 ARCH THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-54986 CUSIP NUMBER NOTIFICATION OF LATE FILING 03939W208 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐Tra

ARTH / Arch Therapeutics, Inc. / Bigger Capital, LLC Passive Investment

SC 13G/A 1 sc13ga110022arth11132024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Arch Therapeutics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securiti

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer o

AMENDMENT NO. 4 SENIOR SECURED CONVERTIBLE PROMISSORY NOTE

Exhibit 10.5 AMENDMENT NO. 4 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 4 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated May 15, 2024, and as subsequently amended on June 30, 2024, August 15, 202

AMENDMENT NO. 6 UNSECURED CONVERTIBLE PROMISSORY NOTE

Exhibit 10.4 AMENDMENT NO. 6 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 6 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on March 15, 2024, and as subsequently amended on April 30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024 (as amended, the “Fourth Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Compan

AMENDMENT NO. 20 SENIOR SECURED CONVERTIBLE PROMISSORY NOTE

Exhibit 10.1 AMENDMENT NO. 20 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 20 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023,

AMENDMENT NO. 20 UNSECURED CONVERTIBLE PROMISSORY NOTE

Exhibit 10.2 AMENDMENT NO. 20 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 20 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 ARCH THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer o

AMENDMENT NO. 15 UNSECURED CONVERTIBLE PROMISSORY NOTE

Exhibit 10.3 AMENDMENT NO. 15 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 15 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024, April 30, 2024, June

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

AMENDMENT NO. 5 UNSECURED CONVERTIBLE PROMISSORY NOTE

Exhibit 10.4 AMENDMENT NO. 5 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 5 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on March 15, 2024, and as subsequently amended on April 30, 2024, June 30, 2024 and August 15, 2024 (as amended, the “Fourth Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder

AMENDMENT NO. 19 UNSECURED CONVERTIBLE PROMISSORY NOTE

Exhibit 10.2 AMENDMENT NO. 19 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 19 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

AMENDMENT NO. 3 SENIOR SECURED CONVERTIBLE PROMISSORY NOTE

Exhibit 10.5 AMENDMENT NO. 3 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 3 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated May 15, 2024, and as subsequently amended on June 30, 2024 and August 15,

AMENDMENT NO. 14 UNSECURED CONVERTIBLE PROMISSORY NOTE

Exhibit 10.3 AMENDMENT NO. 14 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 14 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024, April 30, 2024, June

AMENDMENT NO. 19 SENIOR SECURED CONVERTIBLE PROMISSORY NOTE

Exhibit 10.1 AMENDMENT NO. 19 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 19 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023,

AMENDMENT NO. 1 SECURITIES PURCHASE AGREEMENT

Exhibit 10.6 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 1 to the Securities Purchase Agreement (this “Amendment”) is made and entered into effective September 15, 2024 (the “Amendment No. 1 Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and the Consenting Buyers (as defined below). Capitalized terms not defined herein shall have the

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from N/A to N/A Commission File Number: 000-54986 ARCH THERAPEUTICS, INC.

Form of Amendment No. 13 to the Third 2022 Notes

Exhibit 10.3 AMENDMENT NO. 13 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 13 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024 and April 30, 2024 (as

Form of Amendment No. 4 to the Fourth 2022 Notes

Exhibit 10.4 AMENDMENT NO. 4 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 4 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on March 15, 2024, and as subsequently amended on April 30, 2024 (as amended, the “Fourth Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities

Form of Amendment No. 18 to the Second 2022 Notes

Exhibit 10.2 AMENDMENT NO. 18 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 18 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31

Form of Amendment No. 2 to the First 2024 Notes

Exhibit 10.5 AMENDMENT NO. 2 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 2 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes (the “First Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated May 15, 2024, by and among the Company and the signat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 ARCH THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction of incorporation) (Commission F

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Form of Amendment No. 18 to the First 2022 Notes

Exhibit 10.1 AMENDMENT NO. 18 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 18 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023,

Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 ARCH THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of i

Form of Amendment No. 17 to the Second 2022 Notes

Exhibit 10.2 AMENDMENT NO. 17 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 17 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31

Form of Amendment No. 3 to the Fourth 2022 Notes

Exhibit 10.4 AMENDMENT NO. 3 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 3 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on March 15, 2024, and as subsequently amended on April 30, 2024 (as amended, the “Fourth Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2024 ARCH THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of i

Form of Amendment No. 1 to First 2024 Notes

Exhibit 10.5 AMENDMENT NO. 1 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes (the “First Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated May 15, 2024, by and among the Company and the signat

Form of Amendment No. 17 to the First 2022 Notes

Exhibit 10.1 AMENDMENT NO. 17 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 17 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023,

Form of Amendment No. 12 to the Third 2022 Notes

Exhibit 10.3 AMENDMENT NO. 12 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 12 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024 and April 30, 2024 (as

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 ARCH THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of i

Form of Amendment No. 1 to PIPE Registration Rights Agreement

Exhibit 10.3 AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT This Amendment No. 1 to the Registration Rights Agreement (this “Amendment”) is made and entered into effective July , 2024 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and certain holders of the Company’s securities identified on the signature pages hereto (collectively, the “C

Form of Amendment No. 1 to PIPE Securities Purchase Agreement

Exhibit 10.2 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 1 to the Securities Purchase Agreement (this “Amendment”) is made and entered into effective July , 2024 (the “Amendment No. 1 Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and the Consenting Buyers (as defined below). Capitalized terms not defined herein shall have the same m

Form of Backstop Agreement

Exhibit 10.1 ARCH THERAPEUTICS, INC. BACKSTOP AGREEMENT July , 2024 Reference is made to that certain Securities Purchase Agreement, dated November 8, 2023, as amended (the “SPA”), by and among Arch Therapeutics, Inc., a Delaware corporation (the “Company”) and certain institutional and accredited institutional investors (collectively, the “Buyers”), including the undersigned Buyer. Capitalized te

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Arch Therapeutics, Inc.

As filed with the U.S. Securities and Exchange Commission on June 20, 2024

As filed with the U.S. Securities and Exchange Commission on June 20, 2024 Registration No. 333-268008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A (Amendment No. 5 ) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 3841 46-0524102 (State or other jurisdiction of incor

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of i

Form of IP Security Agreement (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed on May 21, 2024)

Exhibit 10.5 INTELLECTUAL PROPERTY SECURITY AGREEMENT THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (“Agreement”) is entered into as of May , 2024 by and between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), Arch Biosurgery, Inc., a Massachusetts corporation (together with each other Person who becomes a party to this Agreement by execution of a joinder in the form of Exhibit A at

Form of 2024 First Note (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on May 21, 2024)

Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on May 21, 2024)

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May , 2024, between Arch Therapeutics, Inc., a Nevada Corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agre

Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 21, 2024)

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May , 2024 (the “Effective Date”), by ARCH THERAPEUTICS, INC., a Nevada corporation, with headquarters located at 235 Walnut Street, Suite 6, Framingham, MA 01702 (the “Company”), and each buyer identified on the signature pages hereto (each, including it successors and assigns, a “Buyer” a

Form of Security Agreement (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on May 21, 2024)

Exhibit 10.4 SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of May , 2024 between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), Arch Biosurgery, Inc., a Massachusetts corporation (together with each other Person who becomes a party to this Agreement by execution of a joinder in the

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from N/A to N/A Commission File Number: 000-54986 ARCH THERAPEUTICS, INC.

Form of Amendment No. 4 to Registration Rights Agreement

Exhibit 10.2 AMENDMENT NO. 4 TO REGISTRATION RIGHTS AGREEMENT This Amendment No. 4 to the Registration Rights Agreement (this “Amendment”) is made and entered into effective [], 2024 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and certain holders of the Company’s securities identified on the signature pages hereto (collectively, the “Cons

Form of Amendment No. 2 to the Fourth Notes

Exhibit 10.6 AMENDMENT NO. 2 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 2 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on March 15, 2024 (as amended, the “Fourth Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated July 6, 2022, by and

Form of Amendment No. 16 to the First Notes

Exhibit 10.3 AMENDMENT NO. 16 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 16 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Form of Amendment No. 1 to Third A&R Registration Rights Agreement

Exhibit 10.1 AMENDMENT NO. 1 TO THIRD AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment No. 1 to the Third Amended and Restated Registration Rights Agreement (this “Amendment”) is made and entered into effective [], 2024 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and certain holders of the Company’s securities identified

Form of Amendment No. 16 to the Second Notes

Exhibit 10.4 AMENDMENT NO. 16 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 16 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31

Form of Amendment No. 11 to the Third Notes

Exhibit 10.5 AMENDMENT NO. 11 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 11 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024 and March 15, 2024 (as amended, the “T

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Form of Amendment No. 10 to the Third Notes

Exhibit 10.6 AMENDMENT NO. 10 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 10 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023 and January 5, 2024(as amended, the “Third Notes”), iss

Form of Amendment No. 15 to the Second Notes

Exhibit 10.5 AMENDMENT NO. 15 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 15 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 ARCH THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Form of Amendment No. 3 to Securities Purchase Agreement

Exhibit 10.1 AMENDMENT NO. 3 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 3 to the Securities Purchase Agreement (this “Amendment”) is made and entered into effective March 12, 2024 (the “Amendment No. 3 Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and the Consenting Stockholders (as defined below). Capitalized terms not defined herein shall have t

Form of Third A&R Registration Rights Agreement

Exhibit 10.2 THIRD AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Third Amended and Restated Registration Rights Agreement (this “Agreement”) is made and entered into as of March 12, 2024, between Arch Therapeutics, Inc., a Nevada Corporation (the “Company”), and certain holders of the Company’s Notes and Warrants identified on the signature pages hereto (collectively, the “Consenting Sto

Form of Fourth Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Amendment No. 1 to the Fourth Notes

Exhibit 10.7 AMENDMENT NO. 1 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes (the “Fourth Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated July 6, 2022, by and among the Company and the signa

Form of Amendment No. 15 to the First Notes

Exhibit 10.4 AMENDMENT NO. 15 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 15 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023,

Form of Fourth Note

Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 -09-30FY2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from N/A to N/A Commission File Number: 000-54986 ARCH THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-54986 CUSIP NUMBER NOTIFICATION OF LATE FILING 03939W208 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer o

ARTH / Arch Therapeutics, Inc. / Parker Michael Andrew - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 arch13ga.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11) * Arch Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03939W 208 (CUSIP Number) Michael Parker 1928 East Highland Avenue, Suite F104-558 Phoenix, Arizona

Letter from Baker Tilly US, LLP, dated January 12, 2024

Exhibit 16.1 January 12, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentlemen: We are the former independent registered public accounting firm for Arch Therapeutics, Inc. (the “Company”). We have read the Company’s disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” of the Company’s Current Report on Form 8-K dated Ja

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 ARCH THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 ARCH THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Form of Amendment No. 9 to the Third Notes, dated January 5, 2024

Exhibit 10.3 AMENDMENT NO. 9 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 9 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, and November 15, 2023 (as amended, the “Third Notes”), issued by Arch Thera

Form of Amendment No. 14 to the First Notes, dated January 5, 2024

Exhibit 10.1 AMENDMENT NO. 14 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 14 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023,

Form of Amendment No. 14 to the Second Notes, dated January 5, 2024

Exhibit 10.2 AMENDMENT NO. 14 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 14 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-54986 CUSIP NUMBER NOTIFICATION OF LATE FILING 03939W208 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐Tra

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 ARCH THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 ARCH THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

Form of Amendment No. 13 to the Second Notes, dated November 21, 2023

Exhibit 10.2 AMENDMENT NO. 13 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 13 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, and Octobe

Form of Amendment No. 3 to the Bridge Registration Rights Agreement

Exhibit 10.5 AMENDMENT NO. 3 TO REGISTRATION RIGHTS AGREEMENT This Amendment No. 3 to the Registration Rights Agreement (this “Amendment”) is made and entered into effective November 21, 2023 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and certain holders of the Company’s securities identified on the signature pages hereto (collectively,

Form of Amendment No. 13 to the First Notes, dated November 21, 2023

Exhibit 10.1 AMENDMENT NO. 13 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 13 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

Form of Amendment No. 8 to the Third Notes, dated November 21, 2023

Exhibit 10.3 AMENDMENT NO. 8 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 8 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, and October 31, 2023 (as amended, the “Third Notes”), issued by Arch Therapeutics, Inc., a Ne

Form of Amendment No. 3 to Second A&R Registration Rights Agreement

Exhibit 10.4 AMENDMENT NO. 3 TO SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment No. 3 to the Second Amended and Restated Registration Rights Agreement (this “Amendment”) is made and entered into effective November 21, 2023 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and certain holders of the Company’s securities

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer o

Form of Pre-Funded Warrant

Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARCH THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: September [], 2023 CUSIP: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

Form of Amendment No. 2 to Securities Purchase Agreement

Exhibit 10.52.2 AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 2 to the Securities Purchase Agreement (this “Amendment”) is made and entered into effective November [ ], 2023 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and the Consenting Stockholders (as defined below). Capitalized terms not defined herein shall have

Form of 2022 Note Conversion Pre-Funded Warrant

Exhibit 4.11 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer o

Form of PIPE Investor Warrant

Exhibit 4.8 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Amendment No. 12 to Second Notes

Exhibit 10.41.12 AMENDMENT NO. 12 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 12 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023 and September 30, 2023 (as

Form of Amendment No. 12 to First Notes

Exhibit 10.37.12 AMENDMENT NO. 12 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 12 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, and September 30

PIPE Placement Agency Agreement

Exhibit 10.56 PLACEMENT AGENCY AGREEMENT Dawson James Securities, Inc. 101 North Federal Highway, Suite 600 Boca Raton, FL 33432 [], 2023 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Arch Therapeutics, Inc., a Nevada corporation (the “Company”) and Dawson James Securities, Inc. (“Dawson”) pursuant to which Dawson shall serve as the placement agent (the “Pl

Form of Bridge Lock-Up Agreement

Exhibit 10.57 FORM OF LOCK-UP AGREEMENT , 2023 ARCH THERAPEUTICS, INC. 235 Walnut Street, Suite 6 Framingham, MA 01702 Re: Securities Purchase Agreement dated July 7, 2023 Ladies and Gentlemen: This lock-up agreement (the “Agreement”) is being delivered to you in connection with the proposed Securities Purchase Agreement (the “Purchase Agreement”), dated July 7, 2023 between Arch Therapeutics, Inc

Form of True-Up Pre-Funded Warrant

Exhibit 4.10 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of PIPE Placement Agent Warrant

Exhibit 4.9 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Arch Therapeutics, Inc.

Form of Uplist Conversion Warrant

Exhibit 4.12 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of Amendment No. 7 to Third Notes

Exhibit 10.47.7 AMENDMENT NO. 7 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 7 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, and September 30, 2023 (as amended, the “Third Notes”), issued by Arch Therapeutics, Inc., a Nevada corporatio

Form of Amendment No. 2 to Registration Rights Agreement

Exhibit 10.53.2 AMENDMENT NO. 2 TO REGISTRATION RIGHTS AGREEMENT This Amendment No. 2 to the Registration Rights Agreement (this “Amendment”) is made and entered into effective November [ ], 2023 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and certain holders of the Company’s securities identified on the signature pages hereto (collective

Form of Underwriting Agreement

Exhibit 1.1 UNDERWRITING AGREEMENT [●], 2023 DAWSON JAMES SECURITIES, INC. 101 N. Federal Highway Suite 600 Newport Beach, CA 92660 As Representative of the several Underwriters named on Schedule 1 attached hereto Ladies and Gentlemen: The undersigned, Arch Therapeutics, Inc., a Nevada corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with Dawson James Securities Inc. (

Form of Investor Warrant

Exhibit 4.2 COMMON STOCK PURCHASE WARRANT ARCH THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: September [], 2023 CUSIP: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the

Form of PIPE Pre-Funded Warrant

Exhibit 4.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Exchange Investor Warrant

Exhibit 4.13 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of PIPE Securities Purchase Agreement

Exhibit 10.54 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November [●], 2023 (the “Effective Date”), by ARCH THERAPEUTICS, INC., a Nevada corporation, with headquarters located at 235 Walnut Street, Suite 6, Framingham, MA 01702 (the “Company”), and each buyer identified on the signature pages hereto (each, including it successors and assigns, a

As filed with the U.S. Securities and Exchange Commission on November 8, 2023

Table of Contents As filed with the U.S. Securities and Exchange Commission on November 8, 2023 Registration No. 333-268008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A (Amendment No. 4) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 3841 46-0524102 (State or other j

Form of Amendment No. 2 to Second A&R Registration Rights Agreement

Exhibit 10.49.2 AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment No. 2 to the Second Amended and Restated Registration Rights Agreement (this “Amendment”) is made and entered into effective November [ ], 2023 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and certain holders of the Company’s securit

Form of PIPE Registration Rights Agreement

Exhibit 10.55 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of November [●], 2023, between Arch Therapeutics, Inc., a Nevada Corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” or “Holder” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Sec

Form of Pre-Funded Warrant

Exhibit 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARCH THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: September [], 2023 CUSIP: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any

Form of Underwriter Warrant

Exhibit 4.3 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING [●], 2023, WHICH IS THE C

Form of Warrant Agency Agreement

Exhibit 1.2 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of September [], 2023 (“Agreement”), between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and Empire Stock Transfer, a [federally chartered trust company] (the “Warrant Agent”). W I T N E S S E T H WHEREAS, pursuant to a registered offering by the Company of units (the “Units”), each consisting of (a) one sha

Form of Pre-Funded Warrant Agency Agreement

Exhibit 1.3 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of September [], 2023 (“Agreement”), between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and Empire Stock Transfer, a [federally chartered trust company] (the “Warrant Agent”). W I T N E S S E T H WHEREAS, pursuant to a registered offering by the Company of units (the “Units”), each consisting of (a) one sha

As filed with the U.S. Securities and Exchange Commission on October 5, 2023

Table of Contents As filed with the U.S. Securities and Exchange Commission on October 5, 2023 Registration No. 333-268008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A (Amendment No. 3) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 3841 46-0524102 (State or other ju

Form of Underwriting Agreement

Exhibit 1.1 UNDERWRITING AGREEMENT [●], 2023 DAWSON JAMES SECURITIES, INC. 101 N. Federal Highway Suite 600 Newport Beach, CA 92660 As Representative of the several Underwriters named on Schedule 1 attached hereto Ladies and Gentlemen: The undersigned, Arch Therapeutics, Inc., a Nevada corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with Dawson James Securities Inc. (

Calculation of Filing Fee Tables Form S-1 (Form Type) Arch Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)

EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Arch Therapeutics, Inc.

Form of Investor Warrant

Exhibit 4.2 COMMON STOCK PURCHASE WARRANT ARCH THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: September [], 2023 CUSIP: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the

Form of Amendment No. 11 to First Notes, dated September 30, 2023

Exhibit 10.1 AMENDMENT NO. 11 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 11 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, and August 30, 2023 (as amended, the

Form of Amendment No. 11 to Second Notes, dated September 30, 2023

Exhibit 10.2 AMENDMENT NO. 11 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 11 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, and August 30, 2023 (as amended, the “Second No

Form of Amendment No. 6 to Third Notes, dated September 30, 2023

Exhibit 10.3 AMENDMENT NO. 6 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 6 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, and August 30, 2023 (as amended, the “Third Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2023 ARCH THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

-09-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. E

Certificate of Amendment of Articles of Incorporation, as amended, of Arch Therapeutics, Inc., effective September 21, 2023

Exhibit 3.1

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

Arch Therapeutics Provides AC5® Commercialization Update Orders and Paid Claims Increasing Since Rollout of Reimbursement Code

Exhibit 99.1 Arch Therapeutics Provides AC5® Commercialization Update Orders and Paid Claims Increasing Since Rollout of Reimbursement Code FRAMINGHAM, MA – September 13, 2023 – Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first produ

Form of Bridge Placement Agent Warrant

Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

Form of Amendment No. 5 to Third Notes, dated August 30, 2023

Exhibit 10.3 AMENDMENT NO. 5 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 5 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023, July 7, 2023, and July 31, 2023 (as amended, the “Third Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursua

Form of Amendment No. 1 to Registration Rights Agreement

Exhibit 10.6 AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT This Amendment No. 1 to the Registration Rights Agreement (this “Amendment”) is made and entered into effective August 30, 2023 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and certain holders of the Company’s securities identified on the signature pages hereto (collectively, th

Form of Amendment No. 1 to Second A&R Registration Rights Agreement

Exhibit 10.4 AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment No. 1 to the Second Amended and Restated Registration Rights Agreement (this “Amendment”) is made and entered into effective June 17, 2023 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and certain holders of the Company’s securities iden

Form of Amendment No. 1 to Securities Purchase Agreement

Exhibit 10.5 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 1 to the Securities Purchase Agreement (this “Amendment”) is made and entered into effective August 30, 2023 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and the Consenting Stockholders (as defined below). Capitalized terms not defined herein shall have the sa

Form of Amendment No. 10 to Second Notes, dated August 30, 2023

Exhibit 10.2 AMENDMENT NO. 10 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 10 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, and July 31, 2023 (as amended, the “Second Notes”), issued by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 ARCH THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Form of Amendment No. 10 to First Notes, dated August 30, 2023

Exhibit 10.1 AMENDMENT NO. 10 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 10 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, and July 31, 2023 (as amended, the “First Notes”), i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary information statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-6(d)(2)) ☒ Definitive information statement ARCH THERAPEUTICS, INC. (Name of Reg

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Arch Therapeutics, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan

Exhibit 10.1 ARCH THERAPEUTICS, INC. 2023 OMNIBUS EQUITY INCENTIVE PLAN (As amended and restated effective August 22, 2023) 1. Establishment and Purpose 1.1 The purpose of the Arch Therapeutics, Inc. 2023 Omnibus Equity Incentive Plan, as amended and restated effective August 22, 2023 (the “Plan”) is to provide a means whereby eligible employees, officers, non-employee directors and other individu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary information statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-6(d)(2)) ☐ Definitive information statement ARCH THERAPEUTICS, INC. (Name of Reg

Form of Amendment No. 3 to Third Notes

Exhibit 10.19 AMENDMENT NO. 3 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 3 (this “Amendment”), dated as of July 7, 2023, to those certain Unsecured Convertible Promissory Notes (as amended, the “Third Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated July 6, 2022, by and am

Form of Omnibus Amendment to Notes and Warrants

Exhibit 10.20 ARCH THERAPEUTICS, INC. OMNIBUS AMENDMENT TO NOTES AND WARRANTS July 7, 2023 This Omnibus Amendment to Notes and Warrants (this “Amendment”) to those certain (i) “First Notes” (the “First Notes”) (as defined in the Purchase Agreement (as defined below)), (ii) “Second Notes” (the “Second Notes”) (as defined in the Purchase Agreement), (iii) Third Notes (the “Third Notes” and, collecti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from N/A to N/A Commission File Number: 000-54986 ARCH THERAPEUTICS, INC.

Form of Amendment No. 8 to Second Notes

Exhibit 10.18 AMENDMENT NO. 8 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 8 (this “Amendment”), dated as of July 7, 2023, to those certain Unsecured Convertible Promissory Notes (as amended, the “Second Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated July 6, 2022, by and a

Form of Bridge Common Warrant

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Securities Purchase Agreement, dated July 7, 2023, by and among the Company and the signatories thereto

Exhibit 10.24 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 7, 2023 (the “Effective Date”), by ARCH THER

Form of Amendment No. 8 to First Notes

Exhibit 10.17 AMENDMENT NO. 8 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 8 (this “Amendment”), dated as of July 7, 2023, to those certain Senior Secured Convertible Promissory Notes (as amended, the “First Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated July 6, 2022,

Amended and Restated Bylaws, as amended to date

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ARCH THERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.1 Principal Office. The principal offices of the Corporation shall be located at such place as the Board of Directors may from time to time determine. Section 1.2 Other Offices. The Corporation may also have offices at such other places, either within or without the State of Nevada, as the Board of Direc

Form of Bridge Pre-Funded Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Registration Rights Agreement, dated July 7, 2023, by and among the Company and the signatories thereto

Exhibit 10.25 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 7, 2023, between Arch Therapeutics, Inc., a Nevada Corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” or “Holder” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securitie

ARTH / Arch Therapeutics Inc / Stahl Andrew - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Arch Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03939W208 (CUSIP Number) July 12, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

Form of Amendment No. 4 to Third Notes, dated July 31, 2023

Exhibit 10.3 AMENDMENT NO. 4 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 4 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023, and as subsequently amended on July 1, 2023 and July 7, 2023 (as amended, the “Third Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certa

Form of Amendment No. 9 to Second Notes, dated July 31, 2023

Exhibit 10.2 AMENDMENT NO. 9 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 9 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, and July 7, 2023 (as amended, the “Second Notes”), issued by Arch Therapeutics

Form of Amendment No. 9 to First Notes, dated July 31, 2023

Exhibit 10.1 AMENDMENT NO. 9 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 9 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, and July 7, 2023 (as amended, the “First Notes”), issued by Arch The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 ARCH THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of i

ARTH / Arch Therapeutics Inc / wilson brandt - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Arch Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03939W208 (CUSIP Number) July 12, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

Arch Therapeutics, Inc. 2023 Equity Incentive Plan

Exhibit 10.1 ARCH THERAPEUTICS, INC. 2023 OMNIBUS EQUITY INCENTIVE PLAN 1. Establishment and Purpose 1.1 The purpose of the Arch Therapeutics, Inc. 2023 Omnibus Equity Incentive Plan (the “Plan”) is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in the development and

Amendment No. 1 to the Amended and Restated Bylaws, as adopted on July 18, 2023

Exhibit 3.1 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF ARCH THERAPEUTICS, INC. This Amendment No. 1 to the Bylaws of Arch Therapeutics, Inc., a Nevada corporation (the “Company”), as amended to date (the “Bylaws”) is made as of this 18th day of July, 2023. 1. The Bylaws are hereby amended by replacing existing Section 2.10 of Article 2 of the Bylaws, in its entirety with the following:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 ARCH THERAPEUTICS,

-09-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employ

ARTH / Arch Therapeutics Inc / BIGGER CAPITAL FUND L P Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Arch Therapeutics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 03939W208 (CUSIP Number) July 12, 202

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated July 14, 2023 with respect to the Common Stock of Arch Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securiti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 ARCH THERAPEUTICS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of in

ARTH / Arch Therapeutics Inc / Oasis Capital, LLC - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Arch Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03939W208 (CUSIP Number) Oasis Capital, LLC 208 Ponce de Leon Ave Ste 1600 San Juan, Puerto Rico 00918 1-816-960-0100 (Name, Address and Telephone Number of Person Authorized to Receive No

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2023 ARCH THERAPEUTICS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of in

Form of Amendment No. 7 to Second Notes, dated July 1, 2023

Exhibit 10.2 AMENDMENT NO. 7 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 7 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023 and June 15, 2023 (as amended, the “Second Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation

Form of Amendment No. 7 to First Notes, dated July 1, 2023

Exhibit 10.1 AMENDMENT NO. 7 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 7 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023 and June 15, 2023 (as amended, the “First Notes”), issued by Arch Therapeutics, Inc., a Nevada cor

Form of Amendment No. 2 to Third Notes, dated July 1, 2023

Exhibit 10.3 AMENDMENT NO. 2 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 2 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15, 2023 (as amended, the “Third Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated July 6, 2022, by and a

Form of Amendment No. 6 to Second Notes, dated June 15, 2023

Exhibit 10.2 AMENDMENT NO. 6 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 6 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023 and May 15, 2023 (as amended, the “Second Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”)

Form of Amendment No. 6 to First Notes, dated June 15, 2023

Exhibit 10.1 AMENDMENT NO. 6 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 6 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023 and May 15, 2023 (as amended, the “First Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 ARCH THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of i

Form of Amendment No. 1 to Third Notes, dated June 15, 2023

Exhibit 10.3 AMENDMENT NO. 1 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes (the “Third Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated July 6, 2022, by and among the Company and the signatories ther

Form of Amendment No. 5 to Second Notes

Exhibit 10.6 AMENDMENT NO. 5 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 5 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023 and April 15, 2023 (as amended, the “Second Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to certain H

Form of Amendment No. 5 to First Notes

Exhibit 10.5 AMENDMENT NO. 5 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 5 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023 and April 15, 2023 (as amended, the “First Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to

Form of Third Note

Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

Form of Amendment No. 2 to Securities Purchase Agreement, dated May 15, 2023, by and among the Company and the signatories thereto

Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 2 to the Securities Purchase Agreement (this “Amendment”) is made and entered

Form of Third Warrant

Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from N/A to N/A Commission File Number: 000-54986 ARCH THERAPEUTICS, INC.

Form of Second A&R Registration Rights Agreement

Exhibit 10.4 SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Second Amended and Restated Registration Rights Agreement (this “Agreement”) is made and entered into as of May 15, 2023, between Arch Therapeutics, Inc., a Nevada Corporation (the “Company”), and certain holders of the Company’s Notes and Warrants identified on the signature pages hereto (collectively, the “Consenting Sto

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-54986 CUSIP NUMBER NOTIFICATION OF LATE FILING 03939W208 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐Transit

Form of Amendment No. 4 to First Notes, dated April 15, 2023

Exhibit 10.1 AMENDMENT NO. 4 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 4 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023 and March 15, 2023 (as amended, the “First Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder purs

Form of Amendment No. 1 to the A&R Registration Rights Agreement

Exhibit 10.3 AMENDMENT NO. 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment No. 1 to the Amended and Restated Registration Rights Agreement (this “Amendment”) is made and entered into effective April 15, 2023 (the “Amendment Effective Date”) between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and certain holders of the Company’s securities identified on the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2023 ARCH THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Form of Amendment No. 4 to Second Notes, dated April 15, 2023

Exhibit 10.2 AMENDMENT NO. 4 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 4 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023, and as subsequently amended on March 10, 2023 and March 15, 2023 (as amended, the “Second Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to certain Holders pursuant

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Form of Exchange Agreement, dated March 10, 2023

Exhibit 10.1 WARRANT EXCHANGE AGREEMENT This Warrant Exchange Agreement (this “Agreement”), dated as of March 10, 2023 (the “Effective Date”), is entered into by and among Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and the undersigned holders (the “Warrantholders”) of warrants to purchase shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”). R

Form of Amendment No. 3 to Second Notes, dated March 15, 2023

Exhibit 10.5 AMENDMENT NO. 3 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 3 (this “Amendment”), dated as of March 15, 2023, to those certain Unsecured Convertible Promissory Notes, as amended on February 14, 2023 and as subsequently amended on March 10, 2023 (as amended, the “Second Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to certain Holders

Form of Amendment No. 3 to First Notes, dated March 15, 2023

EX-10.4 5 ex489322.htm EXHIBIT 10.4 Exhibit 10.4 AMENDMENT NO. 3 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 3 (this “Amendment”), dated as of March 15, 2023, to those certain Senior Secured Convertible Promissory Notes, as amended on February 14, 2023 and as subsequently amended on March 10, 2023 (as amended, the “First Notes”), issued by Arch Therapeutics, Inc., a Nevada cor

Form of Amendment No. 1 to Series 2 Notes, dated March 10, 2023

Exhibit 10.7 AMENDMENT NO. 1 TO SERIES 2 UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 (this “Amendment”), dated as of March 10, 2023, to those certain Series 2 Unsecured Convertible Promissory Notes (as amended, the “Series 2 Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each note holder (collectively, the “Note Holders”) on November 6, 2020, as

Form of Amendment No. 1 to Series 1 Notes, dated March 10, 2023

Exhibit 10.6 AMENDMENT NO. 1 TO SERIES 1 UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 (this “Amendment”), dated as of March 10, 2023, to those certain Series 1 Unsecured Convertible Promissory Notes (as amended, the “Series 1 Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each note holder (collectively, the “Note Holders”) on June 4, 2020, as ame

Form of Amendment No. 2 to First Notes, dated March 10, 2023

Exhibit 10.2 AMENDMENT NO. 2 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 2 (this “Amendment”), dated as of March 10, 2023, to those certain Senior Secured Convertible Promissory Notes (as amended, the “First Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated July 6, 2022

Form of Amendment No. 2 to Second Notes, dated March 10, 2023

EX-10.3 4 ex489321.htm EXHIBIT 10.3 Exhibit 10.3 AMENDMENT NO. 2 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 2 (this “Amendment”), dated as of March 10, 2023, to those certain Unsecured Convertible Promissory Notes (as amended, the “Second Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Ag

Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services The new code represents a key milestone for the commercialization of AC5® Advanced Wound System in doctors’ offices

Exhibit 99.1 Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services The new code represents a key milestone for the commercialization of AC5® Advanced Wound System in doctors’ offices and other outpatient settings FRAMINGHAM, MA – March 9, 2023 – Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a markete

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of i

Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities Dedicated representation in selected geographic locations to support new and recurring sales in governmen

EX-99.1 2 ex484889.htm EXHIBIT 99.1 Exhibit 99.1 Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities Dedicated representation in selected geographic locations to support new and recurring sales in government facilities FRAMINGHAM, MA – March 7, 2023 – Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “C

Form of Second Note Amendment

Exhibit 10.2 AMENDMENT NO. 1 TO UNSECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 (this “Amendment”), dated as of February 14, 2023, to those certain Unsecured Convertible Promissory Notes (the “Second Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to certain Holders pursuant to that certain Securities Purchase Agreement, dated July 6, 2022, by and among

Form of First Notes Amendment

Exhibit 10.1 AMENDMENT NO. 1 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 (this “Amendment”), dated as of February 14, 2023, to those certain Senior Secured Convertible Promissory Notes (the “First Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement, dated July 6, 2022, by and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 ARCH THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from N/A to N/A Commission File Number: 000-54986 ARCH THERAPEUTICS, INC.

Form of Warrant Agent Agreement

Exhibit 1.2 WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of [ ], 2023 (the “Issuance Date”) is between Arch Therapeutics, Inc. a Nevada corporation (the “Company”), and Empire Stock Transfer Inc., a Nevada corporation (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated [ ], 2023,

Calculation of Filing Fee Tables Form S-1 (Form Type) Arch Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)

EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Arch Therapeutics, Inc.

As filed with the U.S. Securities and Exchange Commission on January 30 , 2023

As filed with the U.S. Securities and Exchange Commission on January 30 , 2023 Registration No. 333-268008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A (Amendment No. 2 ) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 3841 46-0524102 (State or other jurisdiction of i

Form of Investor Warrant

Exhibit 4.2 COMMON STOCK PURCHASE WARRANT ARCH THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exer

ARTH / Arch Therapeutics Inc / Parker Michael Andrew - ARCH THERAPEUTICS, INC. - 13GA Passive Investment

SC 13G/A 1 archsc13ga.htm ARCH THERAPEUTICS, INC. - 13GA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10) * Arch Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03939W 208 (CUSIP Number) Michael Parker 1928 East Highland Avenue, Suite F104-558

ARTH / Arch Therapeutics Inc / Parker Michael Andrew - ARCH THERAPEUTICS, INC. - 13GA Passive Investment

SC 13G/A 1 archsc13ga.htm ARCH THERAPEUTICS, INC. - 13GA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9) * Arch Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03939W 208 (CUSIP Number) Michael Parker 1928 East Highland Avenue, Suite F104-558

Form of Underwriter Warrant

Exhibit 4.3 REPRESENTATIVE’S PURCHASE WARRANT ARCH THERAPEUTICS, INC. Warrant Shares: [●] Initial Exercise Date: [●], 2023 This REPRESENTATIVE’S PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date referr

Filing fee table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Arch Therapeutics, Inc.

Form of Underwriting Agreement

EX-1.1 2 ex466024.htm EXHIBIT 1.1 UNDERWRITING AGMT Exhibit 1.1 [●] UNITS EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK ARCH THERAPEUTICS, INC. UNDERWRITING AGREEMENT [●], 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 As Representative of the Several Underwriters, if any, named in Schedule I hereto Ladies and Gen

As filed with the U.S. Securities and Exchange Commission on January 23, 2023

As filed with the U.S. Securities and Exchange Commission on January 23, 2023 Registration No. 333-268008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 3841 46-0524102 (State or other jurisdiction of inc

Form of Investor Warrant

Exhibit 4.2

Form of Amendment No. 1 to Securities Purchase Agreement, dated January 18, 2023, by and among the Company and the signatories thereto

EX-10.1 2 ex465284.htm EXHIBIT 10.1 Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 1 to the Securities Purchase Agreement (th

Form of Second Warrant

Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of Amended and Restated Registration Rights Agreement, dated January 18, 2023, by and among the Company and the signatories thereto

EX-10.4 5 ex465287.htm EXHIBIT 10.4 Exhibit 10.4 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amended and Restated Registration Rights Agreement (this “Agreement”) is made and entered into as of January 18, 2023, between Arch Therapeutics, Inc., a Nevada Corporation (the “Company”), and certain holders of the Company’s Notes and Warrants identified on the signature pages hereto (collect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 ARCH THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer o

Form of Second Note

Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer o

EX-3.1

EX-3.1 2 ex464621.htm EXHIBIT 3.1 Exhibit 3.1

EX-3.2

Exhibit 3.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54986 ARCH THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 ARCH THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Arch Therapeutics, Inc.

As filed with the U.S. Securities and Exchange Commission on October 25, 2022

As filed with the U.S. Securities and Exchange Commission on October 25, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 3841 46-0524102 (State or other jurisdiction of incorporation or organization

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

ARCH THERAPEUTICS, INC. 12,766,600 Shares of Common Stock Up to 92,560,174 Shares of Common Stock underlying the 2022 Notes Up to 91,412,633 Shares of Common Stock underlying the 2022 Warrants and 2022 Placement Agent Warrants Up to 15,312,493 Shares

Filed Pursuant to Rule 424(b)(4) Registration No. 333-267004 PROSPECTUS ARCH THERAPEUTICS, INC. 12,766,600 Shares of Common Stock Up to 92,560,174 Shares of Common Stock underlying the 2022 Notes Up to 91,412,633 Shares of Common Stock underlying the 2022 Warrants and 2022 Placement Agent Warrants Up to 15,312,493 Shares of Common Stock underlying the Subordinated Conversion Shares This prospectus

As filed with the U.S. Securities and Exchange Commission on August 25, 2022

As filed with the U.S. Securities and Exchange Commission on August 25, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 3841 46-0524102 (State or other jurisdiction of incorporat

August 26, 2022

August 26, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.

Filing fee table

EX-FILING FEES 4 ex415022.htm Exhibit 107 Form S-1 (Form Type) Arch Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.001 par v

Power of Attorney

S-1 1 arch20220819s1.htm As filed with the U.S. Securities and Exchange Commission on August 19, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 3841 46-0524102 (State or other jurisdiction of incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

EX-3.1

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ARCH THERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.1 Principal Office. The principal offices of the Corporation shall be located at such place as the Board of Directors may from time to time determine. Section 1.2 Other Offices. The Corporation may also have offices at such other places, either within or without the State of Nevada, as the Board of Direc

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission (I.R.S. Employer of

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 ARCH THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-54986 46-0524102 (State or other jurisdiction (Commission

Amended and Restated Bylaws, as adopted on August 15, 2022

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ARCH THERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.1 Principal Office. The principal offices of the Corporation shall be located at such place as the Board of Directors may from time to time determine. Section 1.2 Other Offices. The Corporation may also have offices at such other places, either within or without the State of Nevada, as the Board of Direc

PROSPECTUS SUPPLEMENT NO. 11 DATED AUGUST 15, 2022 PROSPECTUS DATED FEBRUARY 8, 2021 (AS SUPPLEMENTED) ARCH THERAPEUTICS, INC. Up to 12,654,163 Shares of Common Stock

424B3 1 arch20220815c424b3.htm FORM 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-234811 PROSPECTUS SUPPLEMENT NO. 11 DATED AUGUST 15, 2022 TO PROSPECTUS DATED FEBRUARY 8, 2021 (AS SUPPLEMENTED) ARCH THERAPEUTICS, INC. PROSPECTUS Up to 12,654,163 Shares of Common Stock This Prospectus Supplement No. 11 supplements the prospectus of Arch Therapeutics, Inc. (the “Company”, “we”, “us”,

PROSPECTUS SUPPLEMENT NO. 10 DATED AUGUST 15, 2022 PROSPECTUS DATED FEBRUARY 8, 2021 (AS SUPPLEMENTED) ARCH THERAPEUTICS, INC. Up to 36,366,691 Shares of Common Stock Underlying Warrants Previously Issued

Filed Pursuant to Rule 424(b)(3) Registration No. 333-234811 PROSPECTUS SUPPLEMENT NO. 10 DATED AUGUST 15, 2022 TO PROSPECTUS DATED FEBRUARY 8, 2021 (AS SUPPLEMENTED) ARCH THERAPEUTICS, INC. PROSPECTUS Up to 36,366,691 Shares of Common Stock Underlying Warrants Previously Issued This Prospectus Supplement No. 11 supplements the prospectus of Arch Therapeutics, Inc. (the ?Company?, ?we?, ?us?, or ?

PROSPECTUS SUPPLEMENT NO. 11 DATED AUGUST 15, 2022 PROSPECTUS ORIGINALLY DATED MARCH 10, 2021, AND AMENDED ON DECEMBER 22, 2021 (AS SUPPLEMENTED) ARCH THERAPEUTICS, INC. Up to 82,078,133 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-253588 PROSPECTUS SUPPLEMENT NO. 11 DATED AUGUST 15, 2022 TO PROSPECTUS ORIGINALLY DATED MARCH 10, 2021, AND AMENDED ON DECEMBER 22, 2021 (AS SUPPLEMENTED) ARCH THERAPEUTICS, INC. PROSPECTUS Up to 82,078,133 Shares of Common Stock This Prospectus Supplement No. 11 supplements the prospectus of Arch Therapeutics, Inc. (the ?Company?, ?we?, ?us?,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from N/A to N/A Commission File Number: 000-54986 ARCH THERAPEUTICS, INC.

PROSPECTUS SUPPLEMENT NO. 10 DATED JULY 11, 2022 PROSPECTUS ORIGINALLY DATED MARCH 10, 2021, AND AMENDED ON DECEMBER 22, 2021 (AS SUPPLEMENTED) ARCH THERAPEUTICS, INC. Up to 82,078,133 Shares of Common Stock

424B3 1 arch20220711c424b3.htm FORM 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-253588 PROSPECTUS SUPPLEMENT NO. 10 DATED JULY 11, 2022 TO PROSPECTUS ORIGINALLY DATED MARCH 10, 2021, AND AMENDED ON DECEMBER 22, 2021 (AS SUPPLEMENTED) ARCH THERAPEUTICS, INC. PROSPECTUS Up to 82,078,133 Shares of Common Stock This Prospectus Supplement No. 10 supplements the prospectus of Arch Therap